HCPCS code S0156 – Exemestane 25 mg billing guide

Key takeaways

HCPCS Code S0156 reports exemestane, 25 mg, so one unit equals one tablet and a 30-tablet fill is billed as 30 units.

S0171 is not the exemestane code. It was bumetanide injection, 0.5 mg, and it was deleted on January 1, 2024.

Medicare Part B does not accept S-series codes, so Medicare patients get exemestane through a Part D pharmacy claim billed by NDC.

Billing software such as Pabau submits S0156 claims from the patient record and tracks each status, so staff re-key less.

HCPCS Code S0156: Definition and code details

HCPCS Code S0156 is an S-series HCPCS Level II code with the official descriptor Exemestane, 25 mg. One billing unit equals one 25 mg tablet. CMS added the code on January 1, 2001, and it is still active.

S-series codes are temporary national codes for the needs of non-Medicare payers, such as state Medicaid programs and commercial insurers. According to the CMS HCPCS overview, Medicare does not use them. The NCI CanMED entry for S0156 confirms the drug as exemestane, brand name Aromasin.

Many billing references and drug databases still pair exemestane with S0171. That pairing is wrong. S0171 was injection, bumetanide, 0.5 mg, a diuretic, and CMS deleted it effective January 1, 2024.

Exemestane: Clinical background and billing context

Exemestane is a steroidal (Type I) aromatase inhibitor for postmenopausal women with hormone receptor-positive (HR+) breast cancer. It binds the aromatase enzyme irreversibly, which lowers estrogen production and slows the growth of estrogen-driven tumors.

Three clinical settings account for most exemestane prescriptions:

• Adjuvant early breast cancer: patients switch to exemestane after two to three years of tamoxifen, to complete five years of hormonal therapy in total.
• Advanced breast cancer: exemestane on its own treats postmenopausal patients whose disease has progressed after tamoxifen.
• Exemestane with everolimus: the FDA-approved combination (Afinitor label, BOLERO-2 trial) treats advanced HR+, HER2-negative disease that progressed on letrozole or anastrozole.

Exemestane is a once-daily tablet that patients take at home. That is why it has an S-code for non-Medicare payers, and why Medicare covers it through the Part D drug benefit. Anastrozole, the other common aromatase inhibitor, follows the same route under HCPCS S0170.

S0156 code at a glance

The reference table below covers the billing attributes coders need before submitting an HCPCS Code S0156 claim.

Which payers accept HCPCS Code S0156?

Some Medicaid programs and commercial payers accept S0156, but many want an NDC-based pharmacy claim instead. Verify the route with each payer. S-series codes are not part of the Medicare Part B fee schedule, and CMS publishes no Part B rate for them.

Medicare Part B vs Part D: Where does exemestane fit?

Exemestane belongs under Medicare Part D, the prescription drug benefit. Oral drugs that patients take at home are covered there, not under the Part B medical benefit. Sending S0156 to Part B is a coverage mismatch that produces an automatic denial.

For Medicare beneficiaries, the pharmacy dispenses exemestane and submits a Part D claim using the National Drug Code (NDC). Many states also have oral chemotherapy parity laws. These limit what a commercially insured patient pays out of pocket, and the claim is coded the same way.

The payer decides the route before anyone counts units, and only one of the three routes carries S0156.

How to bill S0156: Units, NDC and documentation

S0156 billing starts with the unit convention. One unit equals 25 mg of exemestane, which is one standard tablet. A 30-day supply is billed as 30 units, and a 90-day supply as 90 units.

1. Confirm the payer accepts S0156. Not every commercial plan or Medicaid program uses S-series codes. If the payer does not, use J8999 (prescription drug, oral, chemotherapeutic, NOS) or bill by NDC as the payer instructs.
2. Check the code itself. Exemestane is S0156, not S0171. A charge master or drug file that still maps exemestane to S0171 sends a deleted code on every claim.
3. Calculate units from the dispensed quantity. A 30-tablet fill is 30 units. Enter the unit count in Box 24G on the CMS-1500 form.
4. Attach the 11-digit NDC. Most Medicaid programs and many commercial payers require it. Report it in 5-4-2 format with the N4 qualifier and the UN unit qualifier.
5. Include the prior authorization number. If the payer required PA, enter the approval number in Box 23 of the CMS-1500.
6. Link a supporting ICD-10-CM code. The diagnosis must support exemestane’s indication. The next section lists the codes payers expect.

ICD-10 diagnosis codes for S0156

Payers check the linked diagnosis first when they review medical necessity. Use the most specific breast cancer code the record supports.

Specificity matters on audit more than on first submission. An unspecified C50 code rarely causes a denial on its own, but auditors flag it when the chart documents the site and laterality.

Prior authorization requirements for exemestane

Many commercial payers and some state Medicaid programs require prior authorization for exemestane. Requirements vary by plan and policy year, so verify PA status for each patient before dispensing.

• Gather the pathology report confirming hormone receptor-positive status before starting the PA request.
• Document menopausal status. Exemestane is approved for postmenopausal women, and plans check for it.
• Record the treatment setting and line. That means adjuvant after tamoxifen, advanced disease after tamoxifen, or the everolimus combination after letrozole or anastrozole.
• Note prior hormonal therapy if the plan wants evidence that tamoxifen or a non-steroidal aromatase inhibitor was tried.
• Log the PA approval number and expiry date. Adjuvant therapy runs for years, so renewals are routine.

S0156 fee schedule and reimbursement rates

There is no Medicare Part B fee schedule rate for HCPCS Code S0156, because S-series codes sit outside the Part B code set. Each payer sets its own rate.

Medicaid programs usually price oral drugs from the state’s drug pricing basis, such as a wholesale cost benchmark or a maximum allowable cost list. Commercial rates follow contracted formulary pricing and vary by plan tier. For a current figure, check the payer’s fee schedule portal or ask its provider relations team.

Codes commonly confused with HCPCS Code S0156

Three codes get mixed up with S0156 when billing exemestane. S0171 is the most damaging, because it looks plausible and is now deleted.

S0156 vs S0170: Two aromatase inhibitors, two codes

S0156 and S0170 both cover aromatase inhibitors for HR+ breast cancer, and both are oral tablets. The drug, the dose per unit and the NDC all differ, so the codes are not interchangeable.

The NDC is the safeguard. An exemestane NDC cannot match an anastrozole code, so validating the NDC against the code at entry catches the swap before the payer does.

Why S0156 claims get denied and how to fix them

S0156 denials cluster around a few preventable causes. Each comes back with claim denial codes that name the problem. A structured denial management process stops the same error from repeating across patients.

Documentation requirements for clean S0156 claims

Clean documentation costs less to assemble before submission than after a denial. It also anchors medical billing compliance for oral cancer drugs. Keep these elements in the file behind every S0156 claim:

• Prescription with dose and dispensed quantity: confirms the 25 mg strength and the tablet count that units are calculated from.
• Pathology report confirming HR+ status: the primary clinical justification for exemestane.
• Menopausal status and treatment setting: recorded in the prescriber’s note, including any prior tamoxifen therapy.
• PA approval number and expiry date: where the payer required authorization.
• 11-digit NDC of the dispensed product: generic exemestane comes from several manufacturers, so the NDC can change between fills.
• Prescriber NPI: some payers check the prescriber’s specialty on oncology drugs.

Store these records under HIPAA record retention rules, so they are ready when an audit request arrives.

How claims management software keeps S0156 claims clean

An S0156 claim usually fails on a field someone typed twice: the code, the unit count, the NDC or the PA number. Billing staff copy those values from the prescription into a separate tool, then chase the payer by phone when a claim stalls.

Pabau’s claims software for practices submits each claim electronically from the patient record and tracks its status once it goes out. Your team enters the units, NDC and PA number once, and the claim carries what the record already holds.

The payoff is less re-keying and one place to see which S0156 claims are paid, pending or denied. Staff spend their time fixing the few denials instead of hunting for them.

Submit and track S0156 claims in one place

Pabau’s claims management submits your S0156 claims and tracks each status, so billing staff spend less time re-keying claim data and chasing payers.

Book a demo

Conclusion

Start with the code itself. Exemestane is S0156, and any S0171 still sitting in a drug file is a deleted bumetanide code waiting to bounce a claim. Fix that mapping once and it stays fixed.

Then settle the payer route before you count units. Medicare fills go to the pharmacy as Part D claims, and payers without S-codes need J8999 or an NDC claim. After that, the remaining denials come from units, NDCs and PA dates, which a dispensing checklist and a renewal calendar cover.

Pabau submits S0156 claims and tracks every status, so your team re-keys less and spots denials sooner. Book a demo to see how it fits your oral drug billing workflow.

Continue your research

Want to see where drug billing fits in the revenue cycle? What is revenue cycle management walks through the claims workflow from eligibility checks to payment posting.

Looking to keep drug claims clean before they go out? Submitting a clean claim explains the fields and documentation standards that prevent administrative denials.

Frequently asked questions